Who supplies Eli Lilly, who buys from it, and who competes with it. Membership is a disclosed business relationship, not a keyword match, and every row carries the sentence that proves it.
⚡
Supply Chain & Partner Read-Through EngineActive
Proactive revenue read-through alerts whenever Eli Lilly files 8-Ks, announces contracts, or beats guidance.
15 companies with a disclosed relationship to Eli Lilly · 4 asserted but unconfirmed, hidden
| Ticker | Relationship | Role | Price | Market Cap | P/E | 1D | From High | Mentions | Catalyst Materiality | Alert |
|---|---|---|---|---|---|---|---|---|---|---|
| Bioprocessing & Supplies (3) | ||||||||||
| WST | Injectable containment and delivery components | supplier | - | - | - | - | - | 26 | 20% exp79 | |
| BDX | Injection and drug delivery systems | supplier | - | - | - | - | - | 7 | 15% exp77 | |
| A | Analytical instruments | supplier | - | - | - | - | - | 1 | 15% exp77 | |
| Distribution (3) | ||||||||||
| CAH | Drug wholesale and distribution | channel | - | - | - | - | - | 5 | 15% exp77 | |
| MCK | Drug wholesale and distribution | channel | - | - | - | - | - | 4 | 15% exp77 | |
| COR | Drug wholesale and distribution | channel | - | - | - | - | - | 3 | 15% exp77 | |
| Clinical Research (2) | ||||||||||
| ICLR | Clinical research services | supplier | - | - | - | - | - | 9 | 15% exp77 | |
| IQV | Clinical trials and health data | supplier | - | - | - | - | - | 2 | 15% exp77 | |
| Payers & PBMs (2) | ||||||||||
| CI | PBM formulary placement | channel | - | - | - | - | - | 2 | 15% exp77 | |
| CVS | PBM formulary placement and pharmacy | channel | - | - | - | - | - | 2 | 15% exp77 | |
| Retail Channel (1) | ||||||||||
| WMT | Retail pharmacy distribution | channel | - | - | - | - | - | 4 | 15% exp77 | |
| Competitor (4) | ||||||||||
| MRK | Broad pharma pipeline | competitor | - | - | - | - | - | 52 | 20% exp79 | |
| NVO | GLP-1 incretin franchise | competitor | - | - | - | - | - | 5 | 15% exp77 | |
| PFE | Obesity and broad pharma pipeline | competitor | - | - | - | - | - | 4 | 15% exp77 | |
| AMGN | Obesity pipeline | competitor | - | - | - | - | - | 2 | 15% exp77 | |
Every row is backed by a quote from an earnings call or an SEC filing. Mentions counts how often the relationship is named across the last four quarters, which is why the most dependent companies sort to the top of each group. Catalyst Materiality computes hardware bottleneck exposure and priority.